Helmholtz Gemeinschaft


Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients

Item Type:Article
Title:Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients
Creators Name:Mueller, D., Mehling, H., Otto, B., Bergmann-Lips, R., Luft, F.C., Jordan, J. and Kettritz, R.
Abstract:BACKGROUND AND OBJECTIVES: Adverse effects complicate the use of drugs that are prescribed for phosphate control in dialysis patients. Alternative treatment options are needed. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Nicotinic acid inhibits intestinal phosphate reabsorption and increases HDL cholesterol. This study tested the phosphate-lowering and HDL-increasing effect of Niaspan (prolonged-release nicotinic acid) in patients who were undergoing dialysis. Efficacy, safety, and tolerability of Niaspan were prospectively studied. Twenty dialysis patients, who were receiving a stable dosage of a calcium salt-containing drug for phosphate control, received after a 2-wk washout period Niaspan for 12 wk. Patients were started on 375 mg/d, and the dosage was increased every 2 wk to achieve 500, 1000, 1500, and 2000 mg/d, respectively. Clinical and laboratory parameters were prospectively recorded in patients who tolerated a target dosage of > or = 1000 mg/d. RESULTS: Seventeen patients tolerated > or = 1000 mg/d Niaspan (mean dosage 1470 +/- 110 mg/d). Niaspan treatment for 12 wk decreased serum phosphate values from 7.2 +/- 0.5 to 5.9 +/- 0.6 mg/dl (P < 0.015). In contrast, Niaspan did not affect serum calcium levels. A significant increase in HDL cholesterol from 40 +/- 3.2 to 59 +/- 5.5 mg/dl (34%) was also observed with Niaspan (P = 0.0005). CONCLUSIONS: Niaspan effectively lowered serum phosphate levels and significantly increased HDL cholesterol. Niaspan may provide an alternative or adjunctive treatment option in dialysis patients.
Keywords:Calcium, Delayed-Action Preparations, Flushing, HDL Cholesterol, Niacin, Parathyroid Hormone, Phosphates, Prospective Studies, Renal Dialysis
Source:Clinical Journal of the American Society of Nephrology
Publisher:American Society of Nephrology
Page Range:1249-1254
Date:November 2007
Official Publication:https://doi.org/10.2215/CJN.01470307
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library